Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 ...
Beam Therapeutics Inc.’s base editing platform with BEAM-101 has trait-like hematology and RMAT/ODD designations. BEAM thinks this could eventually position it with a potential best-in-class SCD drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback